Treace Medical Concepts, Inc. TMCI 深 沪
已收盘 02-06 16:00:00 美东时间
2.26
+0.220
+10.78%
华盛通- 最 高2.28
- 今 开2.07
- 成交量 201.61万股
- 最 低 2.07
- 昨 收 2.04
- 总市值 1.44亿
- 52周最高 10.30
- 市盈率 静 --
- 换手率 3.16%
- 52周最低 2.015
- 委 比 8.59%
- 总股本 6371.81万
- 历史最高 37.17
- 量 比 2.80
- 振 幅 10.29%
- 历史最低 2.015
- 每 手 1
- 风险率 2.13%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue
Treace Medical Concepts reported $62.1M-$62.5M Q4 2025 revenue, a 9% YoY midpoint decline, but full-year 2025 revenue of $212.3M-$212.7M, a 2% increase. The company added 202 new active surgeons, ending the year with 3,337, a 6% YoY growth. CEO John T. Treace expressed optimism about progress amid headwinds, citing expanding 3D bunion technologies. 2026 outlook includes continued procedure growth despite economic challenges.
01-13 12:05
Treace Announces First Surgical Case Utilizing Lapiplasty® Lightning™ Technology
Treace Medical Concepts announced the successful completion of the first surgery using its new Lapiplasty Lightning technology. This advanced system builds on the company's existing Lapiplasty platform, offering improved efficiency, precision, and streamlined workflows. CEO John Treace highlighted the technology's commitment to innovation and its anticipated mid-2026 market release. Surgeon William DeCarbo praised the technology for its intuitive...
01-08 21:05
美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
The Analyst Verdict: Treace Medical Concepts In The Eyes Of 6 Experts
In the preceding three months, 6 analysts have released ratings for Treace Medi...
01-08 04:00
Stifel Maintains Hold on Treace Medical Concepts, Lowers Price Target to $3
Stifel analyst Rick Wise maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and lowers the price target from $5 to $3.
01-07 22:22
Treace to Present at 44th Annual J.P. Morgan Healthcare Conference
Treace Medical Concepts announced that CEO John T. Treace will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company, focused on advancing bunion surgery technology, developed the Lapiplasty® 3D Bunion Correction System and other solutions for foot deformities. Investors are encouraged to follow updates on its website.
2025-12-30 21:05
美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
2025-12-19 10:15
Treace Medical Enters Into New Five Year $175M Senior Secured Loan Arrangement With Credit Funds Managed By SLR Capital Partners
Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it
2025-12-18 21:35
Treace Medical Secures Up to $175 Million in Debt Financing
Treace Medical Concepts announced a new five-year $175 million senior secured loan arrangement with SLR Capital Partners, including $60 million in term loans, $65 million in additional term loan availability, and a $50 million revolving credit facility. The proceeds were used to repay existing debt. The interest rate is based on SOFR with a 3% floor, and the term loan has 48 months of interest-only payments, extendable by 12 months. The company n...
2025-12-18 13:30
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
2025-11-11 10:49
